ストックスクリーナーアプリを入手
108.33
0.42%
-0.46
アフターアワーズ：
108.44
0.11
+0.10%
Abbott Laboratories (ABT) 最新ニュース
Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media
Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Zacks Investment Research
Abbott Laboratories stock holds valuation premium amid steady earnings - AD HOC NEWS
Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
Abbott Laboratories Profile: Recipients - OpenSecrets
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
US companies face rise in cyber attacks - Reuters
Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - Kalkine Media
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - Kalkine Media
Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS
Abbott ablation device effective at 1 year in complex cases - medtechdive.com
Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
Abbott settlement and Kendamil case add to formula industry scrutiny - FoodNavigator.com
Abbott Introduces America’s First Liquid Baby Formula With Whole Milk - Yahoo Finance
Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector? - Barchart.com
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
How Abbott Labs Is Embracing RFK Jr.'s Make America Healthy Again Movement - Investor's Business Daily
Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends - 24/7 Wall St.
Abbott Laboratories Introduces Similac 360 Total Care Made With Whole Milk in US - marketscreener.com
No mixing: Similac's whole-milk formula launches at powder-like prices - Stock Titan
Abbott Laboratories (ABT) Stock Analysis: A Healthy Outlook With A 6.87% Upside - DirectorsTalk Interviews
Abbott Laboratories (ABT) Could Be 6% Below Fair Value Following Libre Duo FDA Approval - simplywall.st
Abbott wins CE mark for new LAA closure device - medtechdive.com
Abbott Laboratories agrees to $670M settlement over premature infant formula claims - Top Class Actions
Lawsuit accusing Abbott MitraClip of kickbacks will proceed - Courthouse News
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Analyst recommendations: Nvidia, Intuit, BofA, Abbott Laboratories, Google… - marketscreener.com
Why Is Abbott Laboratories (ABT) Launching A First Of Its Kind Diabetes Wearable? - simplywall.st
Abbott Labs Settles Investor Formula Recall Suit for $89 Million - Bloomberg Law News
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients - Yahoo
Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson? - The Motley Fool
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Exact Sciences stock enters new chapter after Abbott acquisition - Ad-hoc-news.de
Abbott Agrees to $670 Million Settlement in Premature Infant Formula Litigation - finance.biggo.com
Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration - TipRanks
TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth - Investing.com
Abbott Laboratories settles multitude of infant formula legal claims - Yahoo Finance
Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation - Yahoo Finance
Abbott agreed to pay $670 million to settle preterm baby formula lawsuits - qz.com
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $115 - Moomoo
Abbott Laboratories stock holds firm after Q2 beat - Ad-hoc-news.de
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies - Times West Virginian
True North Advisors LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Asset Advisors Investment Management LLC Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Exchange Traded Concepts LLC Has $6.85 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Position Raised by Financial & Tax Architects LLC - MarketBeat
Capital Investment Advisory Services LLC Sells 12,335 Shares of Abbott Laboratories $ABT - MarketBeat
ABN Amro Investment Solutions Purchases 19,480 Shares of Abbott Laboratories $ABT - MarketBeat
Alecta Tjanstepension Omsesidigt Acquires 153,500 Shares of Abbott Laboratories $ABT - MarketBeat
BTIG Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $134 - Moomoo
Abbott Inks $670M Deal To End Some Preterm Formula Claims - Law360
Abbott Will Pay $670 Million To End 2,000 Infant Formula Claims - NDTV Profit
Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative? - simplywall.st
Abbott to pay $670 million to settle some preterm infant formula cases - The Lufkin Daily News
Abbott Reaches $670 Million Settlement in Infant Formula Litigation - Devdiscourse
Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge? - Yahoo Finance
1.15%
1.58%
大文字化:
|
ボリューム (24 時間):